Autolus Therapeutics Reports Third Quarter 2026 Financial Results

Autolus Therapeutics reported third-quarter 2026 AUCATZYL net product revenue of $41.2 million, up from $21.1 million a year earlier, with a gross margin of 57%. The company raised its full-year outlook, expecting revenue to meet or exceed the upper end of its previous $150 million forecast. Autolus said its current cash and projected revenues are expected to fund operations into the second quarter of 2028.